Since the description of Turner syndrome (TS) in 1938, a wealth of information has been added and our current understanding of the syndrome is continuously being broadened. The syndrome affects only females and care must include the close collaboration of several specialties such as genetics, embryology, paediatrics, gynaecology and obstetrics, endocrinology, cardiology, gastroenterology, otorhinonology and ophthalmology.
Furthermore, the risk of other conditions such as cirrhosis of the liver (RR 5.7), osteoporosis (RR 10.1) and fractures (RR 2.16) was also increased, as was the risk of congenital malformations of the heart, the urinary system and the face, ears and neck. The risk of all cancers was comparable to that seen in the general female population. 1 In addition to morbidity, mortality is increased in TS. In a British cohort study, the RR of premature death was increased to 4.2 5 owing to disease in the nervous, digestive, cardiovascular, respiratory and genito-urinary systems. Death owing to cancer was lower than expected, corroborating the morbidity studies. We found a comparable increase in mortality among Danish patients, and there were important differences between patients with 45,X or an isochomosome, who had a four-fold increase in mortality, and patients with other karyotypes, who had only a two-fold increase in mortality. 4 
Turner Syndrome and the Heart
Diseases of the heart account for 50% of the excess mortality in TS. 6 A number of left-sided cardiovascular malformations such as elongated transverse aortic arch are seen in 50% of TS women, 7, 8 bicuspid aortic valves are seen in 13-43% compared with 1-2% in the general population 9 and 4-14% have aortic coarctation in TS (see Figure 2 ). 1 Less commonly, right-sided malformations and abnormalities such as persistent left vena cava superior and partial anomalous venous return are encountered. 7 These congenital heart defects may co-segregate at least to some extent, and in some cases they may severely affect the left ventricle, the outflow tract and the thoracic aorta in hypoplastic left heart syndrome.
Some of these defects call for early and potentially life-saving high-risk cardiovascular intervention, thereby contributing to both increased mortality in infancy as well as later on in life as a result of complications caused by the congenital abnormalities, disease and the necessary interventions. 4 Other defects present less acutely, with symptoms associated with late life morbidity. Then again, some women remain subclinical throughout their entire lifetime, with an unresolved place in the pattern of morbidity and mortality in TS.
More than 30% of young girls and adolescents and 50% of adults with TS are mildly hypertensive on 24-hour ambulatory measurements.
Additionally, 50% have abnormal circadian blood pressure profiles. [10] [11] [12] Although the pathological nature underlying the hypertensive disorder in TS remains unknown, it is uniformly accepted that hypertension and the sympathovagal dysfunction of nocturnal 'non-dipping' confer a high risk of future cardiovascular events, as also epidemiologically documented in TS. 4 The presence of these risk factors adds to the other adverse indices of cardiovascular risk in TS: increased carotid intima thickness, 13 a propensity towards glucose intolerance and type 2 diabetes, 11, 14 non-alcoholic steatohepatitis (NASH), [15] [16] [17] discordant lipid profile, 18, 19 oestrogen deficiency and unfavourable body composition. 20 In addition to the congenital structural cardiac malformations such as bicuspid aortic valve and coarctation of the aorta, hypertension is also thought to be a major factor, 21 as shown by the high incidence of aortic dissection and rupture in TS: 40 per 100,000 TS syndrome-years versus six per 100,000 general population years. Strikingly, aortic dissection affects TS patients at a median age of 35 years as opposed to 71 years in the general population (see Figure 3) . 22 Aortic dilation normally precedes dissection and rupture, and such an abnormal aortic calibre is seen in 3-42% of randomly selected TS women 23, 24 increasing with age. 25 Emerging Aspects of Turner Syndrome The congenital and acquired cardiovascular morbidities occur against a backdrop of endocrine problems, creating highly variable cardiac phenotypes where neither risk prediction nor modification is straightforward. Therefore, all girls and women with TS should be regarded as facing an increased risk of cardiovascular events, 30 and it is recommended that TS girls and women be submitted to a baseline delineation of cardiac phenotype and regular follow-ups by cardiologists trained in congenital heart disease. 31 Depending on the presentation, examination should include an electrocardiogram, 24-hour ambulatory blood pressure, echocardiography and magnetic resonance imaging. follicles can still be found in 12-19-year-olds. 33 Antimüllerian hormone (AMH) and inhibin B are emerging as possible markers of ovarian function. 34, 35 Understanding the processes in early follicular apoptosis in TS may in the future lead to a treatment that spares the follicles and maintains fertility.
Ideally, the timing of endocrine therapy should allow onset of puberty at the same time as the peers of the patient to avoid social problems secondary to delayed physical and psychological development. This would also allow optimal bone mineralisation to take place. In most normal girls, puberty starts at around 12 years of age. Since 30% of girls with TS undergo some spontaneous pubertal development and 2-5%
Genetic Disorders Oestrogen therapy should always be co-ordinated with the use of growth hormone (GH). This should be individualised for each patient to optimise both growth and pubertal development. When growth is a priority, delaying oestrogen therapy is an option to avoid compromising adult height. However, recent growth-promoting trials have documented that the physiological timing of oestrogen therapy does not compromise adult height when GH therapy is started early and the dose is increased in a stepwise fashion. 38 Proper oestrogen replacement is also pivotal in TS since it has a positive effect on motor speed and verbal and non-verbal memory and processing when administered in puberty. Females with TS present with a particular neurocognitive profile, with impaired performance on motor tasks and impaired visuo-spatial ability but normal verbal skills. 39 The deficits in cognition are likely caused by haploinsufficiency of X-linked genes that normally escape X-inactivation, but these putative genes await further elucidation.
Infertility is rated as the most prominent problem in adult women with TS. 40 Oocyte donation is an option in many countries and fertility preservation is an emerging option. The most recent studies show good results comparable to thse seen with oocyte donation in other infertile patients, although better preparation of the uterus for implantation (uterine size and endometrial thickness) with prolonged treatment with high daily doses of estradiol (4-6mg or up to 8mg of 17β-estradiol) may improve results in TS. Importantly, it is a high-risk endeavor for a TS woman to go through pregnancy, especially in relation to lesions related to the cardiovascular system but also secondary to endocrine features.
Androgen insufficiency is present, 41 Therefore, SHOX deficiency can explain only part of the height deficit in TS. 52 BNP is a transcriptional target of SHOX and is present alongside SHOX at the growth plate in proliferative chondrocytes. 53 Whether the lack of SHOX-induced BNP is involved in cardiovascular malformations and diseases in TS remains to be elucidated.
GH concentrations in TS are found to be normal in some and reduced in others, and it is generally concluded that girls with TS have a growth deficiency with reduced sensitivity to GH rather than a GH deficiency.
GH treatment can increase growth velocity and final height. The effect is dose-dependent, and normalisation of final height has been shown to be obtainable with high doses. 38 In the only randomised controlled study using GH treatment (0.3mg/kg/week) or placebo, a significant increase in final height of 7.2cm (CI 6.0-8.0) was seen, with HRT started at 13 years of age.
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In cases where the TS diagnosis is made early (before one to two years of age), very early treatment with GH should be instituted. In a randomised, controlled, open-label study including girls with TS nine months to four years of age for GH treatment, it was possible to correct growth failure and promote growth catch-up, bringing 93% of the toddlers back into the normal height range of the background population within two years. By contrast, those in the placebo group were faced with progressive growth failure. 55 Besides effects on growth and final height, GH treatment also has beneficial effects on body composition, with reduced fat mass and an increase in lean body mass. Concerns about the effect of GH on the heart have arisen from evidence that left ventricular hypertrophy is found in acromegalic patients with high levels of GH. A Dutch study showed no signs of left ventricular hypertrophy and no increase in blood pressure in TS girls undergoing seven years of GH treatment.
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Gastroenterology and Hepatology
Increased concentrations of liver enzymes, especially alkaline phosphatase, alanine/aspartase aminotransferase and γ-glutamyl transferase (markers of hepatic cell lesion or turnover), are frequent in TS. Bilirubin (excretion) and coagulation parameters (production) are, in most cases, within the normal range.
In a liver biopsy study in 27 women with TS biopsied because of persistently elevated liver tests, 57 Inflammatory bowel disease (IBD) also seems to be more frequent in TS (2-3%) and should especially be suspected in girls not responding to GH therapy. Coeliac disease is present in 8% of patients 58, 59 and, since it may cause additional growth stunting, it should always be excluded. The usual guidelines should be followed for IBD and coeliac disease. Treatment consisted of estradiol implants (and an oral gestagen cyclically). 46 resulting in comparable estradiol levels to those seen in premenopausal women, and considerably higher than levels achieved with regimens used hitherto (estradiol 2mg orally or equivalent transdermal doses). Bone biopsies pointed towards an anabolic effect on the skeleton of estradiol in young TS patients. 46 Furthermore, GH may improve BMD. In a recent seven-year study with GH treatment given at three different doses, BMD increased in a dose-dependent manner.
Glucose Metabolism and Type 2 Diabetes
However, oestrogen was added after four years of GH treatment, and it is difficult to ascertain the individual effects of GH and oestrogen in this study. 64 No very long-term studies (both follow-up and intervention studies) on the effect of estradiol have been published, but five years of appropriate HRT maintains BMD unchanged. 65 There is a definite need for such studies to determine the ideal treatment regimen during adolescence to achieve two goals: attaining maximal peak bone mass and maintaining BMD without compromising adult height; and 66 
